Compare Noble Corporation plc (NE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Sana Biotechnology Inc — how do they compare? Noble Corporation plc trades at $42.53 (market cap $6.48B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Noble Corporation plc is far larger — about 7.4× Sana Biotechnology Inc's market cap, and Noble Corporation plc pays a 4.93% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NE | SANA | |
|---|---|---|
Market Cap | $6.48B | $873.84M |
Sector | Technology | Health |
52-Week High | $54.37 | $5.92 |
52-Week Low | $25.70 | $2.68 |
Enterprise Value | $7.73B | $848.03M |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $40.60, down 2.17% on the day, with a neutral technical signal. The company reported mixed Q1 2026 earnings, beating expectations, but missed in the prior two quarters. Recent news highlights new offshore drilling contracts, including a $136.2 million Brunei deal, and the upcoming Q2 2026 earnings report on July 27, 2026. Positive cash flow and a dividend payment of $0.50 per share in June 2026 support shareholder returns.
The outlook is cautiously optimistic, supported by new contracts and a consensus price target of $49.75, implying potential upside. Risks include execution on earnings expectations and offshore drilling market volatility. Analyst sentiment is mixed, with 31% Buy ratings, but the stock's current price is near the low end of the target range, suggesting a balanced risk-reward profile.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
